Video

Dr. Szmulewitz on Optimal Use of Radium-223 in mCRPC

Russell Szmulewitz, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the optimal use of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer.

Russell Szmulewitz, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the optimal use of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer.

The optimal use of this agent is unclear, Szmulewitz explains. Though prior data show that patients with mCRPC have a benefit, he says that these patients already have comorbidities. It may be useful to use it in earlier settings in patients with high-volume bone metastases.

Currently in clinical practice, many physicians are using the agent prior to chemotherapy and in patients with bone-metastatic disease. Future studies will likely help demonstrate radium-223's benefit in earier settings, Szmulewitz adds.

Related Videos
Bhavana Pothuri, MD
Kristen Spencer, DO
Laurence Albigès, MD, PhD
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
MATT WAGAR, MD